-
AstraZeneca registers a Phase IIIb study of Capivasertib in China
According to the drug clinical trial registration and information publicity platform of the State Food and Drug Administration, AstraZeneca registered a phase IIIb study (CAPItrue) for advanced breas ... -
AstraZeneca IL-5R α monoclonal antibody approved for market in China
On August 19th, according to the official website of the National Medical Products Administration, AstraZeneca's IL-5R alpha monoclonal antibody (benralizumab) has been approved for listing in China. ...